Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
Melanoma Specific Codon Optimization in Oncolytic Virotherapy
EF 2018-19
Résumé
A cancer cell results from a healthy cell that becomes mutated in specific genes which cause it to divide out of control and resist regular cell death. Around half of all melanoma cases arise from a mutation in a gene called BRAF, with the most common mutation being called BRAFV600E. Tumours which have this mutation often become resistant to chemotherapy and the cancer relapses. Recently, scientists found that the melanoma cells with this BRAFV600E mutation change the way they make proteins from DNA.
Deoxyribonucleic acid (DNA) is essentially an instruction manual to produce proteins, which are components of the cell. One can think of an Ikea manual used to assemble wardrobes. Hypothetically, the Ikea manual could be rewritten in a way that helps the builder assemble the wardrobe more efficiently. Similarly, scientists are able to make small changes in DNA so that the proteins made from it are assembled faster. This proposal outlines a strategy in which we can rewrite the DNA manual so that only the BRAFV600E melanoma can efficiently assemble proteins from it, whereas healthy cells will take much longer. We are interested in this is because our cancer therapy uses viruses to deliver DNA into cancer cells. The DNA that we deliver contains instructions to make toxic proteins that kill the cancer. By redesigning the DNA to make it easy for the melanoma to read, the toxins will be be made efficiently inside the tumour, but poorly in healthy tissues.
I predict this effect will be even more powerful against BRAFV600E tumours that have acquired resistance to chemotherapy, which could make our viruses a beneficial addition to treatment regimens. This idea of “optimizing” DNA for easy-reading in cancer will open doors for improving DNA-based cancer therapies like ours.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
406498
Name
Barkley Russell J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Melanoma Specific Codon Optimization in Oncolytic Virotherapy
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Codon; Codon Optimization; Measles; Melanoma; Oncolytic Virus; Translation; Trna
Abstract
A cancer cell results from a healthy cell that becomes mutated in specific genes which cause it to divide out of control and resist regular cell death. Around half of all melanoma cases arise from a mutation in a gene called BRAF, with the most common mutation being called BRAFV600E. Tumours which have this mutation often become resistant to chemotherapy and the cancer relapses. Recently, scientists found that the melanoma cells with this BRAFV600E mutation change the way they make proteins from DNA.
Deoxyribonucleic acid (DNA) is essentially an instruction manual to produce proteins, which are components of the cell. One can think of an Ikea manual used to assemble wardrobes. Hypothetically, the Ikea manual could be rewritten in a way that helps the builder assemble the wardrobe more efficiently. Similarly, scientists are able to make small changes in DNA so that the proteins made from it are assembled faster. This proposal outlines a strategy in which we can rewrite the DNA manual so that only the BRAFV600E melanoma can efficiently assemble proteins from it, whereas healthy cells will take much longer. We are interested in this is because our cancer therapy uses viruses to deliver DNA into cancer cells. The DNA that we deliver contains instructions to make toxic proteins that kill the cancer. By redesigning the DNA to make it easy for the melanoma to read, the toxins will be be made efficiently inside the tumour, but poorly in healthy tissues.
I predict this effect will be even more powerful against BRAFV600E tumours that have acquired resistance to chemotherapy, which could make our viruses a beneficial addition to treatment regimens. This idea of “optimizing” DNA for easy-reading in cancer will open doors for improving DNA-based cancer therapies like ours.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Barkley, Russell J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~